Skip to main content
Top
Published in: Acta Diabetologica 3/2014

01-06-2014 | Original Article

A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion

Authors: Ezio Bonifacio, Jan Krumsiek, Christiane Winkler, Fabian J. Theis, Anette-Gabriele Ziegler

Published in: Acta Diabetologica | Issue 3/2014

Login to get access

Abstract

We recently developed a novel approach capable of identifying gene combinations to obtain maximal disease risk stratification. Type 1 diabetes has a preclinical phase including seroconversion to autoimmunity and subsequent progression to diabetes. Here, we applied our gene combination approach to identify combinations that contribute either to islet autoimmunity or to the progression from islet autoantibodies to diabetes onset. We examined 12 type 1 diabetes susceptibility genes (INS, ERBB3, PTPN2, IFIH1, PTPN22, KIAA0350, CD25, CTLA4, SH2B3, IL2, IL18RAP, IL10) in a cohort of children of parents with type 1 diabetes and prospectively followed from birth. The most predictive combination was subsequently applied to a smaller validation cohort. The combinations of genes only marginally contributed to the risk of developing islet autoimmunity, but could substantially modify risk of progression to diabetes in islet autoantibody-positive children. The greatest discrimination was provided by risk allele scores of five genes, INS, IFIH1, IL18RAP, CD25, and IL2 genes, which could identify 80 % of islet autoantibody-positive children who progressed to diabetes within 6 years of seroconversion and discriminate high risk (63 % within 6 years; 95 % CI 45–81 %) and low risk (11 % within 6 years; 95 % CI 0.1–22 %; p = 4 × 10−5) antibody-positive children. Risk stratification by these five genes was confirmed in a second cohort of islet autoantibody children. These findings highlight genes that may affect the rate of the beta-cell destruction process once autoimmunity has initiated and may help to identify islet autoantibody-positive subjects with rapid progression to diabetes.
Appendix
Available only for authorised users
Literature
2.
go back to reference Achenbach P, Bonifacio E, Ziegler AG (2005) Predicting type 1 diabetes. Curr Diabetes Rep 5(2):98–103CrossRef Achenbach P, Bonifacio E, Ziegler AG (2005) Predicting type 1 diabetes. Curr Diabetes Rep 5(2):98–103CrossRef
3.
go back to reference Bingley PJ, Gale EA (2006) Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 49(5):881–890PubMedCrossRef Bingley PJ, Gale EA (2006) Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 49(5):881–890PubMedCrossRef
4.
go back to reference Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS, Type 1 Diabetes Genetics Consortium (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703–707PubMedCentralPubMedCrossRef Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS, Type 1 Diabetes Genetics Consortium (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703–707PubMedCentralPubMedCrossRef
5.
go back to reference Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA (1996) The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 59:1134–1148PubMedCentralPubMed Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA (1996) The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 59:1134–1148PubMedCentralPubMed
7.
go back to reference Tait BD, Colman PG, Morahan G, Marchinovska L, Dore E, Gellert S, Honeyman MC, Stephen K, Loth A (2003) HLA genes associated with autoimmunity and progression to disease in type 1 diabetes. Tissue Antigens 61:146–153PubMedCrossRef Tait BD, Colman PG, Morahan G, Marchinovska L, Dore E, Gellert S, Honeyman MC, Stephen K, Loth A (2003) HLA genes associated with autoimmunity and progression to disease in type 1 diabetes. Tissue Antigens 61:146–153PubMedCrossRef
8.
go back to reference Winkler C, Lauber C, Adler K, Grallert H, Illig T, Ziegler AG, Bonifacio E (2011) An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes 60:685–690PubMedCentralPubMedCrossRef Winkler C, Lauber C, Adler K, Grallert H, Illig T, Ziegler AG, Bonifacio E (2011) An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes 60:685–690PubMedCentralPubMedCrossRef
9.
go back to reference Lempainen J, Hermann R, Veijola R, Simell O, Knip M, Ilonen J (2012) Effect of the PTPN22 and INS risk genotypes on the progression to clinical type 1 diabetes after the initiation of β-cell autoimmunity. Diabetes 61:963–966PubMedCentralPubMedCrossRef Lempainen J, Hermann R, Veijola R, Simell O, Knip M, Ilonen J (2012) Effect of the PTPN22 and INS risk genotypes on the progression to clinical type 1 diabetes after the initiation of β-cell autoimmunity. Diabetes 61:963–966PubMedCentralPubMedCrossRef
10.
go back to reference Steck AK, Wong R, Wagner B, Johnson K, Liu E, Romanos J, Wijmenga C, Norris JM, Eisenbarth GS, Rewers MJ (2012) Effects of non-HLA gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population with high-risk HLA-DR, DQ genotypes. Diabetes 61:753–758PubMedCentralPubMedCrossRef Steck AK, Wong R, Wagner B, Johnson K, Liu E, Romanos J, Wijmenga C, Norris JM, Eisenbarth GS, Rewers MJ (2012) Effects of non-HLA gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population with high-risk HLA-DR, DQ genotypes. Diabetes 61:753–758PubMedCentralPubMedCrossRef
11.
go back to reference Winkler C, Krumsiek J, Lempainen J, Achenbach P, Grallert H, Giannopoulou E, Bunk M, Theis FJ, Bonifacio E, Ziegler AG (2012) A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes Immun 13(7):549–555PubMedCrossRef Winkler C, Krumsiek J, Lempainen J, Achenbach P, Grallert H, Giannopoulou E, Bunk M, Theis FJ, Bonifacio E, Ziegler AG (2012) A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes Immun 13(7):549–555PubMedCrossRef
12.
go back to reference Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef
13.
go back to reference TEDDY Study Group (2007) The environmental determinants of diabetes in the young (TEDDY) study: study design. Pediatr Diabetes 8:286–298CrossRef TEDDY Study Group (2007) The environmental determinants of diabetes in the young (TEDDY) study: study design. Pediatr Diabetes 8:286–298CrossRef
14.
go back to reference Schmid S, Buuck D, Knopff A, Bonifacio E, Ziegler AG (2004) BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with type 1 diabetes by delaying exposure to gluten. Diabetologia 47(6):1130–1131PubMedCrossRef Schmid S, Buuck D, Knopff A, Bonifacio E, Ziegler AG (2004) BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with type 1 diabetes by delaying exposure to gluten. Diabetologia 47(6):1130–1131PubMedCrossRef
15.
go back to reference Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG (2011) Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34:1301–1305PubMedCentralPubMedCrossRef Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG (2011) Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34:1301–1305PubMedCentralPubMedCrossRef
16.
go back to reference Puavilai G, Chanprasertyotin S, Sriphrapradaeng A (1999) Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 44:21–26PubMedCrossRef Puavilai G, Chanprasertyotin S, Sriphrapradaeng A (1999) Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 44:21–26PubMedCrossRef
17.
go back to reference Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pflüger M, Illig T, Bonifacio E, Ziegler AG (2009) Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 52:1881–1888PubMedCrossRef Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pflüger M, Illig T, Bonifacio E, Ziegler AG (2009) Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 52:1881–1888PubMedCrossRef
18.
go back to reference Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating Laboratories (2008) Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51:846–852PubMedCrossRef Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating Laboratories (2008) Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51:846–852PubMedCrossRef
19.
go back to reference Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ, Participating Laboratories (2010) Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies. Diabetologia 53:2611–2620PubMedCrossRef Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ, Participating Laboratories (2010) Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies. Diabetologia 53:2611–2620PubMedCrossRef
20.
go back to reference Schenker M, Hummel M, Ferber K, Walter M, Keller E, Albert ED, Janka HU, Kastendiek C, Sorger M, Louwen F, Ziegler AG (1999) Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with type I diabetes: the German BABYDIAB study. Diabetologia 42:671–677PubMedCrossRef Schenker M, Hummel M, Ferber K, Walter M, Keller E, Albert ED, Janka HU, Kastendiek C, Sorger M, Louwen F, Ziegler AG (1999) Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with type I diabetes: the German BABYDIAB study. Diabetologia 42:671–677PubMedCrossRef
21.
go back to reference Walter M, Albert E, Conrad M, Keller E, Hummel M, Ferber K, Barratt BJ, Todd JA, Ziegler AG, Bonifacio E (2003) IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1 diabetes and associated autoimmunity. Diabetologia 46:712–720PubMedCrossRef Walter M, Albert E, Conrad M, Keller E, Hummel M, Ferber K, Barratt BJ, Todd JA, Ziegler AG, Bonifacio E (2003) IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1 diabetes and associated autoimmunity. Diabetologia 46:712–720PubMedCrossRef
22.
go back to reference Fawcett T (2006) An introduction to ROC analysis. Pattern Recognit Lett 27:861–874CrossRef Fawcett T (2006) An introduction to ROC analysis. Pattern Recognit Lett 27:861–874CrossRef
24.
go back to reference Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473–2479PubMedCrossRef Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473–2479PubMedCrossRef
25.
go back to reference Howson JM, Cooper JD, Smyth DJ, Walker NM, Stevens H, She JX, Eisenbarth GS, Rewers M, Todd JA, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Pociot F, Rich SS, Type 1 Diabetes Genetics Consortium (2012) Evidence of gene–gene interaction and age-at-diagnosis effects in type 1 diabetes. Diabetes 61(11):3012–3017PubMedCentralPubMedCrossRef Howson JM, Cooper JD, Smyth DJ, Walker NM, Stevens H, She JX, Eisenbarth GS, Rewers M, Todd JA, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Pociot F, Rich SS, Type 1 Diabetes Genetics Consortium (2012) Evidence of gene–gene interaction and age-at-diagnosis effects in type 1 diabetes. Diabetes 61(11):3012–3017PubMedCentralPubMedCrossRef
26.
go back to reference Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, Nutland S, Coleman G, Himsworth M, Hardy M, Burren O, Healy B, Walker NM, Koch K, Ouwehand WH, Bradley JR, Wareham NJ, Todd JA, Wicker LS (2009) Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 41(9):1011–1015PubMedCentralPubMedCrossRef Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, Nutland S, Coleman G, Himsworth M, Hardy M, Burren O, Healy B, Walker NM, Koch K, Ouwehand WH, Bradley JR, Wareham NJ, Todd JA, Wicker LS (2009) Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 41(9):1011–1015PubMedCentralPubMedCrossRef
27.
go back to reference Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P (2007) Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39(3):329–337PubMedCentralPubMedCrossRef Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P (2007) Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39(3):329–337PubMedCentralPubMedCrossRef
28.
go back to reference Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899):271–275PubMedCrossRef Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899):271–275PubMedCrossRef
29.
go back to reference Liu H, Leung BP (2006) CD4+ CD25+ regulatory T cells in health and disease. Clin Exp Pharmacol Physiol 33(5–6):519–524PubMedCrossRef Liu H, Leung BP (2006) CD4+ CD25+ regulatory T cells in health and disease. Clin Exp Pharmacol Physiol 33(5–6):519–524PubMedCrossRef
30.
go back to reference Durinovic-Belló I, Wu RP, Gersuk VH, Sanda S, Shilling HG, Nepom GT (2010) Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun 11(2):188–193PubMedCentralPubMedCrossRef Durinovic-Belló I, Wu RP, Gersuk VH, Sanda S, Shilling HG, Nepom GT (2010) Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun 11(2):188–193PubMedCentralPubMedCrossRef
31.
go back to reference Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, Simell O, Knip M, Ilonen J (2006) Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 49(6):1198–1208PubMedCrossRef Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, Simell O, Knip M, Ilonen J (2006) Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 49(6):1198–1208PubMedCrossRef
Metadata
Title
A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion
Authors
Ezio Bonifacio
Jan Krumsiek
Christiane Winkler
Fabian J. Theis
Anette-Gabriele Ziegler
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0526-2

Other articles of this Issue 3/2014

Acta Diabetologica 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.